Medical regulators actually approved something useful for a change. Kenya's health ministry has recommended authorizing a new HIV prevention drug called Lenacapavir. The long-acting medicine requires only two injections per year, blocking the virus from establishing itself in the body. This offers an alternative to daily oral PrEP pills that many people struggle to take consistently due to stigma or routine challenges.
The Pharmacy and Poisons Board completed a review of the drug's safety and effectiveness. Health Cabinet Secretary Aden Duale stated the decision aligns with World Health Organization guidance. Kenya joins a small group of African nations in recommending this registration, showcasing its regulatory capacity. The injectable solution could transform protection for high-risk populations.
Global health partners have prioritized Kenya for the initial rollout. Officials are planning how to distribute the drug fairly to those most vulnerable to HIV infection. The ministry emphasized it will only approve products meeting strict safety standards. This move supports the broader goal of ending the public health threat of HIV nationwide.
The Pharmacy and Poisons Board completed a review of the drug's safety and effectiveness. Health Cabinet Secretary Aden Duale stated the decision aligns with World Health Organization guidance. Kenya joins a small group of African nations in recommending this registration, showcasing its regulatory capacity. The injectable solution could transform protection for high-risk populations.
Global health partners have prioritized Kenya for the initial rollout. Officials are planning how to distribute the drug fairly to those most vulnerable to HIV infection. The ministry emphasized it will only approve products meeting strict safety standards. This move supports the broader goal of ending the public health threat of HIV nationwide.
